HUMANISED ANTIBODIES TO AMYLOID BETA Russian patent published in 2015 - IPC C07K16/18 C12N5/10 C12N15/13 C12N15/63 A61K39/395 A61P25/28 A61P27/00 A61P37/00 G01N33/53 

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to field of biotechnology. Claimed is humanised antibody and its fragment, able to specifically bind beta-amyloid, characterised by fragments of sequences based on mouse antibody 8F5, and Fc-region of human IgG1, containing amino acid D265A substitution, as well an coding nucleic acid, expression vector, producing antibody or its cell fragment, method of producing antibody or its fragment; composition, application of antibody and its fragment for medication manufacturing, method of prevention, treatment or alleviation of amyloidosis effects; method of diagnosing amyloid-associated diseases or states, method of determining degree of amyloidogenic plaques and test-set for detection and diagnostics of amyloid-associated plaques.

EFFECT: claimed antibody possesses ability of specific binding with beta-amyloid monomers and highly molecular beta-amyloid polymers, which can be applied in therapy of amyloidoses.

29 cl, 20 dwg, 6 tbl, 16 ex